Here, Alva and colleagues discuss current management options for patients with nonmetastatic upper tract urothelial cancer (UTUC), considering the rationale for perioperative chemotherapy, reviewing existing evidence for adjuvant and neoadjuvant chemotherapy, and contemplating future directions for UTUC management.
- Ajjai S. Alva
- Surena F. Matin
- Arlene O. Siefker-Radtke